Metagenomi Therapeutics, Inc. (MGX)
0.9326
-0.09
(-8.57%)
USD |
NASDAQ |
Oct 13, 13:16
Metagenomi Therapeutics Debt to Equity Ratio : 0.3351 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.3351 |
| March 31, 2026 | 0.2844 |
| December 31, 2025 | 0.2564 |
| September 30, 2025 | 0.2335 |
| June 30, 2025 | 0.2195 |
| March 31, 2025 | 0.209 |
| December 31, 2024 | 0.1949 |
| September 30, 2024 | 0.1801 |
| Date | Value |
|---|---|
| June 30, 2024 | 0.1779 |
| March 31, 2024 | 0.1744 |
| December 31, 2023 | 0.2241 |
| September 30, 2023 | 0.208 |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 0.0684 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 173.70M |
| Total Liabilities (Quarterly) | 61.13M |
| Shareholders Equity (Quarterly) | 112.57M |
| Current Ratio | 4.504 |
| Net Debt Paydown Yield | 2.99% |